For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
3
views
55
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      522
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Telehealth in breast cancer following the coronavirus disease 2019 pandemic

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak, a respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, a pandemic. During this time, cancer patients were heavily impacted and their treatment plans were changed due to measures to fight the disease and solutions had to be found to maintain their follow-up and management from a distance. Some cancer groups worldwide have recommended then the use of telemedicine for oncology patients to ensure the continuity of medical care during the pandemic. This method was considered effective and clinicians worldwide continued using telehealth even after the cessation of worldwide restrictions. To this end, current up-to-date data on the use of telemedicine in BC patient after the COVID-19 outbreak are summarized in this narrative review.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          Hyuna Sung, Jacques Ferlay, Rebecca Siegel … (2021)
          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
          Article 0 comments Cited 29749 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

            Ahmedin Jemal, Lindsey A Torre, Rebecca Siegel … (2018)
            This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Article 0 comments Cited 26742 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

              Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo … (2018)
              In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014.
              Article 0 comments Cited 1469 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Jean Zeghondy:
                ORCID: https://orcid.org/0000-0001-8811-4085
                Role: ConceptualizationRole: InvestigationRole: Writing—original draftRole: Writing—review & editing
                Elie Rassy:
                ORCID: https://orcid.org/0000-0002-7906-0991
                Role: InvestigationRole: Writing—review & editing
                Pietro Lapidari: Role: Data curationRole: Writing—review & editing
                Roland Eid: Role: Data curationRole: Writing—review & editing
                Barbara Pistilli:
                ORCID: https://orcid.org/0000-0002-9184-7199
                Role: ConceptualizationRole: MethodologyRole: ValidationRole: Writing—review & editingRole: Supervision
                Carminia Maria Della Corte: Role: Academic Editor
                Journal
                Journal ID (nlm-ta): Explor Target Antitumor Ther
                Journal ID (iso-abbrev): Explor Target Antitumor Ther
                Journal ID (publisher-id): ETAT
                Title: Exploration of Targeted Anti-tumor Therapy
                Publisher: Open Exploration Publishing
                ISSN (Electronic): 2692-3114
                Publication date (Print): 2023
                Publication date (Electronic): 26 December 2023
                Volume: 4
                Issue: 6
                Pages: 1249-1259
                Affiliations
                University of Campania “Luigi Vanvitelli”, Italy; Nicola Normanno, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Italy
                Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
                Author notes
                *Correspondence: Jean Zeghondy, Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France. jean.zeghondy@ 123456gustaveroussy.fr
                Author information
                https://orcid.org/0000-0001-8811-4085
                https://orcid.org/0000-0002-7906-0991
                https://orcid.org/0000-0002-9184-7199
                Article
                Publisher-manuscript ID: 1002195
                DOI: 10.37349/etat.2023.00195
                PMC ID: 10776597
                SO-VID: 4ed0932b-f3d4-4298-8fa8-de67b9f7971c
                Copyright © © The Author(s) 2023.
                License:

                This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                Date received : 03 February 2023
                Date accepted : 07 November 2023
                Categories
                Subject: Review

                Keywords: telehealth,telemedicine,breast cancer,breast neoplasms,coronavirus disease 2019,pandemic
                Data availability:
                Keywords: telehealth, telemedicine, breast cancer, breast neoplasms, coronavirus disease 2019, pandemic

                Comments

                Comment on this article